Audeara Limited

AUA

Audeara Ltd. engages in the development of noise-cancelling consumer headphones. The company is headquartered in Fortitude Valley, Queensland. The company went IPO on 2021-05-18. The firm specializes in listening solutions for people with hearing challenges. Its principal activity is development of hearing health technology. Its headphones deliver personalized audio to users via Bluetooth headphones. Its headphones are categorized as an assistive listening device (ALD), which can be paired with its mobile application called the Audeara App. Its technology is compatible for use with cochlear implants and hearing aids. The Audeara App uses a personalized algorithm to calibrate the headphones for an individual’s hearing profile. This provides clear sound quality for video conferencing and telephone calls and using mainstream applications like watching television, listening to music, and gaming. Its products include A-01 Headphones, BT-01 Transceiver, A-02 Headphones and A-02 TV Bundle. The company sells its products through distributors and resellers in Australia and North America, and via e-commerce channels.

AUB Group Limited

AUB

AUB Group Ltd.Provides equity based insurance broker network.It operates under the following segments: Australian Broking, New Zealand, Australian Agencies, and Support Service. The company is headquartered in Sydney, New South Wales and currently employs 2,433 full-time employees. The company went IPO on 2005-11-16. Its segments include Australian Broking, New Zealand Broking, Agencies, Tysers and Support service. The Australian Broking segment assesses the insurable risks and risk appetite of customers and sources relevant insurance products from insurers and underwriters which meet the needs of the customer. The Agencies segment assesses, on behalf of the insurer, the risk profile of the end customer and pricing of policies requested by brokers. The New Zealand Broking segment provides broking services within the New Zealand market. The Tysers segment includes wholesale and retail broking and managing general agents. The Support Services segment provides a range of services to support the Australian Broking, Agencies, and New Zealand Broking and Tysers segments, and external clients. Retail broking provides retail broking services within the United Kingdom market.

Activeport Group Ltd

ATV

ActivePort Group Ltd. develops software. The company is headquartered in Perth, Western Australia. The company went IPO on 2021-10-20. Its segments include ActivePort Software, Managed Service Provider (MSP), Network and Corporate services. Its assets are its network orchestration software, its network-as-service platform, and its information systems managed services business. The ActivePort software business offers software to customers that use it to orchestrate their networks and connect their customers to the cloud. The network as a service (NaaS) platform called Global Edge enables organizations to connect their operations to the cloud using a self-service Web interface. The managed services business delivers mission-critical information technology, services and support to enterprise customers across Australia and parts of Southeast Asia. The company helps its customers provide on-demand services, network device configuration and connections to cloud providers.

Amplia Therapeutics Limited

ATX

Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The firm is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The firm's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The firm's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.